BSE Live
Jan 19, 09:50Prev. Close
1509.00
Open Price
1509.60
Bid Price (Qty.)
1498.30 (11)
Offer Price (Qty.)
1500.70 (1)
NSE Live
Jan 19, 09:50Prev. Close
1509.90
Open Price
1509.90
Bid Price (Qty.)
1498.80 (11)
Offer Price (Qty.)
1499.90 (1)
| Profit & Loss account of Ipca Laboratories (in Rs. Cr.) | Mar 15 | Mar 14 | Mar 13 | Mar 12 | Mar 11 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| INCOME | ||||||
| Revenue From Operations [Gross] | 3,079.89 | 3,213.86 | 2,763.74 | 2,319.76 | 1,879.14 | |
| Less: Excise/Sevice Tax/Other Levies | 31.80 | 32.04 | 24.67 | 19.26 | 12.78 | |
| Revenue From Operations [Net] | 3,048.09 | 3,181.82 | 2,739.07 | 2,300.50 | 1,866.36 | |
| Total Operating Revenues | 3,085.14 | 3,234.82 | 2,778.42 | 2,329.37 | 1,881.10 | |
| Other Income | 35.77 | 21.43 | 18.66 | 12.92 | 8.51 | |
| Total Revenue | 3,120.91 | 3,256.25 | 2,797.08 | 2,342.29 | 1,889.61 | |
| EXPENSES | ||||||
| Cost Of Materials Consumed | 1,087.80 | 1,097.51 | 1,044.75 | 871.43 | 721.62 | |
| Purchase Of Stock-In Trade | 123.12 | 90.49 | 106.08 | 100.88 | 94.64 | |
| Operating And Direct Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Changes In Inventories Of FG,WIP And Stock-In Trade | -67.87 | -60.63 | -59.77 | -65.04 | -48.69 | |
| Employee Benefit Expenses | 539.63 | 477.86 | 376.57 | 322.20 | 261.59 | |
| Finance Costs | 25.62 | 24.58 | 31.30 | 39.36 | 28.45 | |
| Depreciation And Amortisation Expenses | 177.17 | 100.89 | 84.00 | 65.31 | 55.43 | |
| Other Expenses | 881.96 | 896.46 | 752.78 | 639.21 | 432.87 | |
| Total Expenses | 2,767.43 | 2,627.16 | 2,335.71 | 1,973.35 | 1,545.91 | |
| Profit/Loss Before Exceptional, ExtraOrdinary Items And Tax | 353.48 | 629.09 | 461.37 | 368.94 | 343.70 | |
| Exceptional Items | 4.25 | 0.00 | 0.00 | 0.00 | -9.96 | |
| Profit/Loss Before Tax | 357.73 | 629.09 | 461.37 | 368.94 | 333.74 | |
| Tax Expenses-Continued Operations | ||||||
| Current Tax | 74.50 | 135.00 | 92.68 | 83.55 | 73.25 | |
| Less: MAT Credit Entitlement | 0.00 | 0.00 | 0.00 | 8.90 | 0.00 | |
| Deferred Tax | 27.12 | 16.72 | 37.30 | 13.23 | 1.42 | |
| Tax For Earlier Years | 0.00 | 0.00 | 0.00 | 0.89 | 3.70 | |
| Total Tax Expenses | 101.62 | 151.72 | 129.98 | 88.77 | 78.37 | |
| Profit/Loss After Tax And Before ExtraOrdinary Items | 256.11 | 477.37 | 331.39 | 280.17 | 255.37 | |
| Profit/Loss From Continuing Operations | 256.11 | 477.37 | 331.39 | 280.17 | 255.37 | |
| Profit/Loss For The Period | 256.11 | 477.37 | 331.39 | 280.17 | 255.37 | |
| OTHER ADDITIONAL INFORMATION | ||||||
| EARNINGS PER SHARE | ||||||
| Basic EPS (Rs.) | 20.29 | 37.83 | 26.27 | 22.23 | 20.36 | |
| Diluted EPS (Rs.) | 20.29 | 37.83 | 26.27 | 22.22 | 20.35 | |
| VALUE OF IMPORTED AND INDIGENIOUS RAW MATERIALS STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Raw Materials | 373.51 | 433.65 | 416.77 | 355.79 | 240.39 | |
| Indigenous Raw Materials | 527.64 | 490.34 | 486.44 | 403.43 | 385.33 | |
| STORES, SPARES AND LOOSE TOOLS | ||||||
| Imported Stores And Spares | 1.97 | 5.63 | 3.53 | 3.43 | 2.66 | |
| Indigenous Stores And Spares | 206.52 | 25.02 | 21.68 | 16.25 | 10.62 | |
| DIVIDEND AND DIVIDEND PERCENTAGE | ||||||
| Equity Share Dividend | 12.62 | 63.10 | 50.47 | 40.29 | 40.21 | |
| Tax On Dividend | 2.57 | 10.72 | 8.38 | 6.54 | 6.62 | |
| Equity Dividend Rate (%) | 50.00 | 250.00 | 200.00 | 160.00 | 160.00 |
12.01.2026
11.01.2026
05.12.2025
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
26.11.2025
Ipca Labs Consolidated September 2025 Net Sales at Rs 2,556.50 crore, up 8.56% Y-o-Y
24.11.2025
Ipca Labs Standalone September 2025 Net Sales at Rs 1,930.32 crore, up 6.59% Y-o-Y
05.09.2025
Ipca Labs Standalone June 2025 Net Sales at Rs 1,746.90 crore, up 11.56% Y-o-Y
10.06.2025
Ipca Labs Standalone March 2025 Net Sales at Rs 1,638.44 crore, up 8.46% Y-o-Y
13.07.2022
Ipca Lab Q1 PAT may dip 41.4% YoY to Rs 179.8 cr: ICICI Direct
08.07.2022
Ipca Laboratories Q1 PAT may dip 36.5% YoY to Rs 194.9 cr: Prabhudas Lilladher
14.04.2022
Ipca Laboratories Q4 PAT may dip 12% YoY to Rs 141.9 cr: Prabhudas Lilladher
13.01.2022
Ipca Laboratories Q3 PAT may dip 32.4% YoY to Rs 179.6 cr: Prabhudas Lilladher